Related Experiment Videos
Phase I study of pirarubicin
A A Miller1, M E Scheulen, U R Kleeberg
1Innere Klinik (Tumorforschung), West German Tumor Center, University of Essen, Federal Republic of Germany.
Journal of Cancer Research and Clinical Oncology
|January 1, 1988
Summary
Pirarubicin (4'-O-tetrahydropyranyl-doxorubicin) showed dose-limiting hematologic toxicity in a Phase I trial. Some patients with metastatic breast cancer experienced partial remission, indicating potential efficacy.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Pirarubicin is a novel doxorubicin analog.
- Phase I trials are crucial for evaluating new cancer therapeutics.
Purpose of the Study:
- To assess the toxicity profile of pirarubicin.
- To obtain preliminary efficacy data for pirarubicin in cancer patients.
Main Methods:
- A dose-escalation Phase I clinical trial was conducted.
- Pirarubicin doses ranged from 30 to 70 mg/m2.
- Toxicity and treatment response were evaluated in 19 evaluable patients.
Main Results:
- Hematologic toxicity was dose-limiting and dose-dependent.
- Common adverse events included nausea, vomiting, alopecia, and stomatitis.
- No acute cardiotoxicity was observed.
Conclusions:
- Pirarubicin demonstrated a manageable toxicity profile with dose-limiting hematologic effects.
- Preliminary efficacy was observed in two pretreated metastatic breast cancer patients, warranting further investigation.